Literature DB >> 8428265

Plasminogen activator inhibitor 2 reduces peritoneal fibrinolytic activity in inflammation.

S A Whawell1, M N Vipond, D M Scott-Coombes, J N Thompson.   

Abstract

Fibrinolysis in peritoneal tissue may play a role in the development of intra-abdominal adhesions. The plasminogen-activating capacity of human peritoneum results largely from the presence of tissue plasminogen activator (tPA). Inflammation reduces peritoneal plasminogen-activating activity and leads to the appearance of plasminogen activator inhibitor (PAI) type 1. The role of PAI-2 in the inhibition of peritoneal fibrinolysis during inflammation was investigated in this study. The plasminogen-activating activity of peritoneal biopsy homogenates (seven inflamed, seven normal), measured using a fibrin plate technique, was reduced in inflamed compared with normal tissue (median < 0.07 versus 13.9 units/cm2, P < 0.01); tPA antigen levels were not significantly different (median 1.02 versus 1.34 ng/ml). PAI-1 and PAI-2 antigens were not detected in normal human peritoneum but were present in inflamed peritoneum (median concentration 8.8 ng/ml for PAI-1, 26.7 ng/ml for PAI-2). These inhibitors may be important factors in adhesion formation by contributing to the abolition of peritoneal plasminogen-activating activity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8428265     DOI: 10.1002/bjs.1800800134

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  2 in total

1.  Effect of sirolimus in the prevention of adhesions around intraabdominal prosthetic graft.

Authors:  Muhip Kanko; Ersan Ozbudak; Ali Ozerdem; Ahmet Aksoy; Metehan Kilic; K Turan Berki
Journal:  World J Surg       Date:  2006-09       Impact factor: 3.352

2.  Macrophage and T-lymphocyte infiltrates in human peritoneal adhesions indicate a chronic inflammatory disease.

Authors:  Marcel Binnebösel; Rafael Rosch; Karsten Junge; Petra Lynen-Jansen; Volker Schumpelick; Uwe Klinge
Journal:  World J Surg       Date:  2008-02       Impact factor: 3.352

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.